Epigenetic therapy in urologic cancers: an update on clinical trials

Epigenetic dysregulation is one of many factors that contribute to cancer development and progression. Numerous epigenetic alterations have been identified in urologic cancers including histone modifications, DNA methylation changes, and microRNA expression. Since these changes are reversible, effor...

Descripción completa

Detalles Bibliográficos
Autores principales: Faleiro, Inês, Leão, Ricardo, Binnie, Alexandra, de Mello, Ramon Andrade, Maia, Ana-Teresa, Castelo-Branco, Pedro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355359/
https://www.ncbi.nlm.nih.gov/pubmed/28036257
http://dx.doi.org/10.18632/oncotarget.14226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355359/
https://www.ncbi.nlm.nih.gov/pubmed/28036257
http://dx.doi.org/10.18632/oncotarget.14226

Ejemplares similares